JURNAL INFO KESEHATAN,
Journal Year:
2023,
Volume and Issue:
21(4), P. 823 - 830
Published: Dec. 31, 2023
SARS-CoV-2
is
the
causative
agent
of
disease
known
as
COVID-19.
COVID-19
spreading
very
fast
around
world.
One
immune
responses
that
play
a
role
in
against
infection
production
antibodies,
which
3
weeks
after
infection.
Where
within
infection,
antibodies
will
be
produced
RBD
and
S1
S2
domains
glycoprotein
S
nucleocapsid
protein
N.
The
ability
an
antibody
to
inhibit
viral
determined
by
its
level
or
titer.
This
study
aims
determine
description
levels
vaccination.
type
research
descriptive
research.
Measurement
for
SRBD
was
carried
out
using
CLIA
method
MAGLUMI
tool.
Of
30
respondents,
23
people
had
received
third
vaccine.
results
this
showed
average
respondents
with
2
doses
vaccine
(1.063,786
BAU/mL)
higher
than
(535.651
BAU/mL).
Vaccine
intervals
more
6
months
(908.338
have
1-6
(228.006
conclusion
highest
titers
are
>6
vaccination,
still
detectable
12
further
research,
it
can
measured
from
who
got
vaccination
duration
years
more.
Journal of Drug Delivery and Therapeutics,
Journal Year:
2024,
Volume and Issue:
14(3), P. 44 - 47
Published: March 15, 2024
Background:
Vaccine
is
an
essential
tool
to
limit
the
health
of
COVID
-19
pandemic
and
one
vaccines
that
got
permitted
used
AstraZeneca
Vaccine.
The
base
viral
vector
vaccine.
This
vaccine
has
a
more
advanced
method
uses
modified
virus
trigger
antibodies
make
herd
immunity
for
people.
Objective:
To
found
correlation
between
antibody
titer
than
incidence
Covid
infection
after
complete
dose
vaccination
on
sociodemographics
Method:
Observasional
prospective
Cohort
was
use
in
this
study
with
convenience
sampling
design.
Inclusion
criteria
were
all
Indonesian
citizens
above
18
years
old
(n=113)
who
vaccinated
at
UTA
45
Jakarta
Center
no
history
before
had
filled
up
informed
consents.
Results:
there
43
(38%)
respondents
infected
Covid-19
full
dosesConclusion:
Base
study,
it
doses
AstraZeneca,
gender,
age,
comorbid,
smoking,
drinking
(P-value
<
0.05)).
Keywords:
Astrazeneca
vaccine,
Antibody
titer,
COVID-19.
IMC Journal of Medical Science,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 8
Published: Sept. 2, 2024
Background
and
objectives:
COVID-19
vaccination
program
has
become
a
global
priority
to
combat
the
worldwide
pandemic.
Studies
claimed
that
severity
case
fatality
could
be
minimized
by
vaccination.
The
durability
of
antibodies
developed
after
is
crucial
for
preventing
COVID-19.
purpose
this
study
was
investigate
dynamics
antibody
responses
an
inactivated
SARS-CoV-2
virus
vaccine
over
time.
Materials
method:
conducted
from
November
2021
2022
among
young
adults.
A
pre-tested
structured
questionnaire
used
record
socio-demographic
clinical
data
all
participants.
All
participants
were
vaccinated
with
two
doses
Sinopharm
vaccine.
Blood
samples
collected
estimation
IgG
spike
S1
protein
indirect
ELISA.
Biochemical
parameters
namely
random
blood
sugar
(RBS),
lipid
profile,
total
protein,
thyroid
stimulating
hormone
(TSH),
FT4
(free
thyroxin)
vitamin
D
levels
determined
in
baseline
standard
methods.
Result:
Total
348
adults,
aged
18-28
years,
enrolled
which
35.3%
64.7%
male
female
respectively.
Out
participants,
51.7%
seropositive
anti-
before
receiving
Seropositivity
not
significantly
(p
>0.05)
different
at
1
month
1st
dose
4
7
months
2nd
increased
<0.05)
compared
pre-vaccination
rate.
Compared
level,
mean
(p<0.05)
following
Among
41
seronegative
(non-immune)
individuals,
seropositivity
(<0.05)
having
adequate
insufficient/deficient
levels.
Conclusion:
revealed
good
proportion
adults
possessed
90%
High
level
persisted
July
2024;
Vol.
18(2):012.
DOI:https://doi.org/10.55010/imcjms.18.024
*Correspondence:
Nehlin
Tomalika,
Department
Community
Medicine
&
Public
Health,
Ibrahim
Medical
College,
1/A,
Sarani,
Segunbagicha,
Dhaka
1000,
Bangladesh.
Email:
[email protected]
Diagnostyka Laboratoryjna,
Journal Year:
2024,
Volume and Issue:
60(4), P. 249 - 258
Published: Dec. 19, 2024
Background:
Vaccination
against
COVID-19
activates
the
cellular
and
humoral
immune
response.Aim:
The
aim
of
study
was
to
determine
anti-SARS-CoV-2
IgG
(CoV2-IgG)
T
lymphocyte
responseto
specific
SARS-CoV-2
stimuli
by
releasing
interferon
gamma
(IFN-γ)
compounds,as
well
as
impact
previous
COVID-19,
age,
BMI
on
tested
parameters
in
healthyvolunteers
six
months
after
vaccination.Material
methods:
We
assessed
concentration
with
an
indirect
chemiluminescencetest
IFN-γ
release
assay
(IGRA).Results:
CoV2-IgG
present
all
subjects
(n
=
80),
but
not
volunteers
were
positive
for
IGRA
(n=
62).
concentrations
both
higher
people
who
had
contracted
before
thetest.
IGRA-S1-positive
group
than
IGRA-S1-borderlinegroup.
Age
(R
–0.237,
p
0.05)
–0.343,
0.003)
negatively
correlated
concentrationof
antibodies
no
history
COVID-19.
IgGand
positively
0.384,
0.001)
among
vaccinated
people.Conclusions:
A
moderate
similarity
observed
entire
cellularpost-vaccination
effects.
infection
followed
vaccination
may
result
amore
robust
response
itself.
On
other
hand,
responsemay
be
impaired
its
ability
mount
effective
following
age.The
seems
affected
BMI,
while
furthersteps
leading
successful
production
increasing
body
mass.
Egyptian journal of Immunology,
Journal Year:
2023,
Volume and Issue:
30(04), P. 30 - 39
Published: Oct. 1, 2023
Coronavirus
disease
2019
(COVID-19)
pandemic
has
urged
the
scientific
community
internationally
to
find
answers
in
terms
of
therapeutics
and
vaccines
control
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2).
The
post
vaccination
immune
response
differs
between
individuals
especially
health
care
workers
who
are
first
line
defense
combat
this
disease.
Our
aim
was
measure
levels
anti-IgG
antibodies
titer
COVID-19
among
Suez
Canal
University
Hospital.
study
included
141
healthcare
workers.
Of
these,
54
were
physicians,
80
nurses,
6
service
workers,
one
security
guard.
We
used
Roche
Elecsys
Anti-SARS-CoV-2
assay
for
serological
detection
IgG.
Seropositive
found
96.5%
participants,
43.3%
them
had
evidence
prior
history
infection.
highest
titers
IgG
sera
youngest
age
groups
(20
–
<35)
years
with
a
mean
335.1
U/
ml.
Participants
received
Sinovac
vaccine
titer,
354.6U/ml;
followed
by
Sinopharm
(mean
352.15
U/ml)
then
Pfizer
Moderna
(311.7U/ml)
AstraZeneca
least
level
(267.31U/ml).
Fatigue
most
significant
short
side
effect
occurring
34%
participants.
In
conclusion,
there
rising
serum
post-vaccine,
better
antibody
those
previously
infected
COVID-19.
post-COVID-19
affected
age,
infection,
type
while
effects
post-vaccination
may
be
vaccine.
JURNAL INFO KESEHATAN,
Journal Year:
2023,
Volume and Issue:
21(4), P. 823 - 830
Published: Dec. 31, 2023
SARS-CoV-2
is
the
causative
agent
of
disease
known
as
COVID-19.
COVID-19
spreading
very
fast
around
world.
One
immune
responses
that
play
a
role
in
against
infection
production
antibodies,
which
3
weeks
after
infection.
Where
within
infection,
antibodies
will
be
produced
RBD
and
S1
S2
domains
glycoprotein
S
nucleocapsid
protein
N.
The
ability
an
antibody
to
inhibit
viral
determined
by
its
level
or
titer.
This
study
aims
determine
description
levels
vaccination.
type
research
descriptive
research.
Measurement
for
SRBD
was
carried
out
using
CLIA
method
MAGLUMI
tool.
Of
30
respondents,
23
people
had
received
third
vaccine.
results
this
showed
average
respondents
with
2
doses
vaccine
(1.063,786
BAU/mL)
higher
than
(535.651
BAU/mL).
Vaccine
intervals
more
6
months
(908.338
have
1-6
(228.006
conclusion
highest
titers
are
>6
vaccination,
still
detectable
12
further
research,
it
can
measured
from
who
got
vaccination
duration
years
more.
